Outcome
| Type |
Measure |
Description |
Time frame |
Safety issue |
| Other |
Personal relevance (Patients) |
The relevance and importance of the intervention for informing the patient's health-related decision making will be assessed using a modified version of the Systematic Processing scale. This scale is measured on a 7-point Likert scale (1 = completely disagree; 7 = completely agree), with higher scores representing greater systematic processing and personal relevance. |
From enrollment through 18 months post-intervention |
|
| Other |
Perceived disease risk (Patients) |
Self-reported perceptions of smoking-related disease risks will be assessed using the Perceived Susceptibility and Severity subscales. Possible scores for the susceptibility subscale range from 1 (very unlikely) to 7 (very likely), and possible scores for the severity subscale range from 1 (not at all severe) to 5 (extremely severe), with higher scores representing greater perceived susceptibility and severity of disease. |
From baseline through 18 months post-intervention |
|
| Other |
Perceived benefits of screening and treatment (Patients) |
Patients' perceived importance and benefits of receiving lung cancer screening and smoking cessation medications will be assessed using a modified version of the Beliefs and Attitudes about Bupropion scale. The scale is measured on a 5-point Likert scale (1 = not at all; 5 = extremely), with higher scores representing greater perceived benefits of lung cancer screening and smoking cessation medications. |
From baseline through 18 months post-intervention |
|
| Other |
Perceived benefits of screening and treatment (Clinicians) |
Clinicians' perceived importance and benefits of eligible patients receiving lung cancer screening and smoking cessation medications will be assessed using a modified version of the Beliefs and Attitudes about Bupropion scale. The scale is measured on a 5-point Likert scales (1 = not at all; 5 = extremely), with higher scores representing greater perceived benefits of lung cancer screening and smoking cessation medications. |
exit interview [after last patient is enrolled per clinician at the time of the last intervention (approximately 3 years) |
|
| Other |
Patient-centeredness of care discussions regarding screening and treatment (Patients) |
Patients' perceptions on the extent to which clinician-patient discussions focused on patient-specific needs, preferences, and information regarding lung cancer screening and tobacco treatment will be assessed using the Perceived Involvement in Care Scale (PICS). The scale is measured on a 5-point Likert scale (1 = strongly disagree; 5 = strongly agree), with higher scores representing greater patient-centeredness in care discussions. |
From enrollment through 18 months post-intervention |
|
| Other |
Patient-centeredness of care discussions regarding screening and treatment (Clinicians) |
Clinicians' perceptions on the extent to which clinician-patient discussions focused on patient-specific needs, preferences, and information regarding lung cancer screening and tobacco treatment will be assessed using the Perceived Involvement in Care Scale (PICS). The scale is measured on a 5-point Likert scale (1 = strongly disagree; 5 = strongly agree), with higher scores representing greater patient-centeredness in care discussions. |
exit interview [after last patient is enrolled per clinician at the time of the last intervention (approximately 3 years)] |
|
| Primary |
Clinician ordering of lung cancer screening |
This will be quantified by the proportion of screen-eligible patients who receive a clinician order for lung cancer screening. |
From enrollment through 6 months post-intervention |
|
| Primary |
Patient completion of lung cancer screening |
This will be quantified by the proportion of screen-eligible patients who complete lung cancer screening. |
From enrollment through 6 months post-intervention |
|
| Secondary |
Clinician ordering of lung cancer screening |
This will be quantified by the proportion of screen-eligible patients who receive a clinician order for lung cancer screening. |
From enrollment through 18 months post-intervention |
|
| Secondary |
Patient completion of lung cancer screening |
This will be quantified by the proportion of screen-eligible patients who complete lung cancer screening. |
From enrollment through 18 months post-intervention |
|
| Secondary |
Patient completion of lung cancer screening, of those with order for screening |
This will be quantified by the proportion of screen-eligible patients with an order for lung cancer screening who complete lung cancer screening. |
From enrollment through 18 months post-intervention |
|
| Secondary |
Patient ongoing adherence to annual repeat lung cancer screening |
This will be quantified by the proportion of screen-eligible patients who complete a repeat annual lung cancer screening |
From enrollment through 18 months post-intervention |
|
| Secondary |
Clinician prescribing of tobacco treatment |
This will be quantified by the proportion of screen-eligible current smokers who receive a clinician order for tobacco treatment (medication and/or counseling). |
From enrollment through 18 months post-intervention |
|
| Secondary |
Patient use of tobacco treatment |
This will be quantified by the proportion of screen-eligible current smokers who use tobacco treatment (medication and/or counseling). |
From enrollment through 18 months post-intervention |
|
| Secondary |
Readiness to quit smoking |
This will be quantified by the proportion of current smokers in the stage of change classifications of Precontemplation, Contemplation, Preparation, or Action. |
From baseline through 18 months post-intervention |
|
| Secondary |
Smoking heaviness |
This will be quantified by the average number of cigarettes smoked per day in the past 30 days. |
From baseline through 18 months post-intervention |
|
| Secondary |
Smoking abstinence |
This will be quantified by a self-reported 7-day point prevalence. |
From baseline through 18 months post-intervention |
|
